CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Mitesco Incorporated

A Mission to Improve Healthcare. Mitesco, Inc. (OTCQB: MITI) is a public, development stage company whose mission is to acquire and implement technologies and services to improve the quality of care, reduce cost, and enhance consumer convenience. We are focused on developing a portfolio of companies that provide healthcare technology solutions and the team is adept at deal structures supportive of long term organizational value. The holding company structure facilitates profitable growth and enables acquired business to focus on scale. The MITI portfolio of companies will apply leading-edge solutions that emphasize stakeholder value and are based upon sector trends.

Myocor

Myocor is a Osseo, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stryker Sustainability Solutions

Stryker Sustainability Solutions is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keas

Keas is the leading Health Management platform for employers. We offer Wellbeing programs, coaching, benefits integration, and wellness incentives. Keas is dedicated to helping employers reduce health costs by reducing population health risks and encouraging smarter buying choices in healthcare. With over 70% of preventable healthcare spend wasted today, Keas leverages cutting-edge technologies in data science and behavioral economics to change behavior and slash waste, once and for all.

ABK Biomedical

ABK Biomedical Inc. combines a compelling clinical market need with innovative biomaterials invented by Drs. Bob Abraham, Daniel Boyd and Sharon Kehoe.